Skip to main content

Table 1 Population demographic and clinical characteristics for male sub-cohorts

From: The use of mono- and combination drug therapy in men and women with lower urinary tract symptoms (LUTS) in the UK: a retrospective observational study

   LUTS (including OAB)
N = 12,383
BPO only
N = 36,307
Age at index date n 12,383 36,307
  Mean (SD) 65.54 (15.73) 67.98 (12.47)
  18–24 192 (1.6%) 119 (0.3%)
  25–34 434 (3.5%) 356 (1.0%)
  35–44 736 (5.9%) 997 (2.7%)
  45–54 1438 (11.6%) 3586 (9.9%)
  55–64 2188 (17.7%) 7746 (21.3%)
  65–74 3379 (27.3%) 11,905 (32.8%)
  ≥ 75 4016 (32.4%) 11,598 (31.9%)
Index of multiple deprivation at index prescription (GP surgery level) n 5112 16,534
  1 = least deprived 633 (12.4%) 2770 (16.8%)
  2 1124 (22.0%) 3654 (22.1%)
  3 968 (18.9%) 3175 (19.2%)
  4 963 (18.8%) 2926 (17.7%)
  5 = most deprived 1424 (27.9%) 4009 (24.2%)
New comorbidities n 12,383 36,307
Count of newly diagnosed chronic diseases from the QOF within the 12-month pre-index period Mean (SD) 0.21 (0.50) 0.22 (0.51)
  0 10,228 (82.6%) 29,480 (81.2%)
  1 1790 (14.5%) 5700 (15.7%)
  2 313 (2.5%) 978 (2.7%)
  3+ 52 (0.4%) 149 (0.4%)
Polypharmacy n 12,383 36,307
Number of distinct BNF headers within the 12-month pre-index period Mean (SD) 9.81 (7.27) 8.52 (6.45)
  0 576 (4.7%) 1757 (4.8%)
  [1; 3] 1931 (15.6%) 6668 (18.4%)
  [4; 7] 2936 (23.7%) 10,342 (28.5%)
  [8; 19] 5707 (46.1%) 15,220 (41.9%)
  20+ 1233 (10.0%) 2320 (6.4%)
Antimuscarinic treatment experience within the 12-month pre-index period n 12,383 36,307
  Yes 908 (7.3%) 397 (1.1%)
  No 11,475 (92.7%) 35,910 (98.9%)
  1. Male LUTS (including OAB) sub-cohort patients were those receiving an OAB drug (antimuscarinic and/or mirabegron) with or without a BPO drug (either an alpha-blocker and/or 5-ARI). Male BPO sub-cohort patients were those receiving an alpha-blocker and/or 5-ARI without an OAB drug. Percentages may not total exactly 100 due to rounding
  2. BNF: British National Formulary; BPO: benign prostatic obstruction; GP: general practitioner; LUTS: lower urinary tract symptoms; OAB: overactive bladder; QOF: Quality and Outcomes Framework; SD: standard deviation